Expected (0) patent expiry date (patent number) in |
INN (1) |
Originator's Trade mark |
Patent holder (2) (manufacturer) |
Basic patent priority date (number) |
International patent application |
RepresentativeEuropean corresponding patent |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| |
|
|
|
|
|
Brazil (3) |
Cambodia (4) |
China (5) |
Guatemala (6) |
Kenya |
Malawi (7) |
OAPI (8) |
Peru (9) |
South Africa |
Thailand (10) |
Uganda (11) |
Ukraine |
Zambia (7) |
Zimbabwe |
Amphotericin B |
Fungizone |
Olin Mathieson (Bristol Myers Squibb) |
28.12.1954 (US478014) |
No |
No |
No |
No |
No |
No |
No |
No |
No |
No |
No |
No |
No |
No |
No |
No |
liposomal |
Ambisome |
Vestar (Gilead-NeXstar) |
12.11.1987 (US119518) |
No |
EP0317120 |
No |
No |
No |
No |
No |
No |
? |
No |
No |
No |
No |
No |
No |
No |
Arthemeter+ Lumefantrine (benflutemol) |
Coartem/Riamet (13) |
Ciba-Geigy (Novartis) |
08.08.1990 (CN106722) |
WO92/02217 |
EP0500823 |
No |
No |
08.08.05
(CN1058717) |
No |
12.06.11 (AP231) |
12.06.07 (AP231) |
? |
No |
12.06.11 (ZA9104490) |
No |
31.01.08 (AP231) |
? |
12.06.07 (AP231) |
12.06.11 (AP231) |
Azithromycin |
Sumamed |
Pliva (+Pfizer) |
06.03.1981 (YU592) |
No |
GB2094293 |
No |
No |
No |
No |
No |
No |
No |
No |
No |
No |
No |
No |
No |
No |
crystalline dihydrate |
Zithromax |
Pfizer |
09.07.1987 (PCT/US87/01612) |
WO89/00576 |
EP298650 |
No |
No |
08.07.03
(CN1016785) |
No |
15.06.08 (AP44) |
15.06.04 (AP44) |
abandoned (OA8743) |
No |
07.07.08 (ZA8804925) |
No |
27.07.04 (AP44) |
? |
15.06.04 (AP44) |
15.06.08 (AP44) |
Ciprofloxacin |
Cipro, Ciproxin |
Bayer |
03.09.1980 (DE3033157) |
No |
EP0049355 |
No |
No |
No |
No |
expired 21.08.01 (KE3545) |
No |
No |
No |
expired 01.09.01 (ZA8106080) |
No |
No |
No |
No |
No |
tablet formulation (12) |
Cipro, Ciproxin |
Bayer |
21.01.1986 (DE3601566) |
No |
EP0230881 |
No |
No |
expired 21.01.02
(CN1084188) |
No |
No |
No |
No |
No |
No |
No |
No |
No |
No |
No |
Fluconazole (general) |
|
ICI |
02.06.1980 (GB8017959) |
No |
EP0044605 |
No |
No |
No |
No |
expired 14.05.01 (KE3733) |
No |
No |
No |
expired 19.05.01
(ZA8103354) |
No |
No |
No |
No |
No |
specific |
Diflucan |
Pfizer |
06.06.1981 (GB8117379) |
No |
EP0069442 |
No |
No |
No |
No |
expired 22.04.02 (KE3771) |
No |
No |
No |
expired 04.06.02 (ZA8203934) |
No |
No |
expired 01.06.02 (UA8019) |
No |
No |
Footnotes:
(0) Except when stated differently, this expiry date is 20 years from the filling date, but note that the patent may expire before if the patent holder abandons it (i.e. stops paying the annual fees).
(1) Patents may be granted to protect the basic molecule of a medicine, but also
e.g. to protect the manufacturing process, a specific therapeutic indication, or a specific formulation of the said molecule. Note that a product patent usually covers also a manufacturing process.
(2) Note that only the first patent holder is named where there are more than one.
(3) In Brazil, patent protection for pharmaceuticals was only introduced on May 14th 1997. However, between May 15th 1996 and May 15th 1997 it was possible to register a preexisting foreign patent or pending patent application in Brazil in order to obtain pipeline patent protection, i.e., patent protection for medicines which are patent protected abroad but which have not been marketed yet.
(4) There is no patent law in force in Cambodia. A draft Patent Law was passed by the National Assembly on November 28th 2002. This law is then supposed to go to the Senate for confirmation and is expected to be in force in 2003.
(5) Chinese Patent Law was amended, with effect on January 1st 1993, to extend patent protection from 15 to 20 years.
(6) Guatemala only introduced patent protection for pharmaceuticals on November 1st 2000.
(7) In Malawi and Zambia, patents are granted for an initial term of 16 years from the filing date, with a possible extension.
(8) OAPI patents are effective in the 16 member States of the Organisation Africaine de la Propriété Intellectuelle (Benin, Burkina Faso, Cameroon, Central African Rep., Congo, Ivory Coast, Gabon, Guinea, Guinea Bissau, Equatorial Guinea, Mali, Mauritania, Niger, Senegal, Chad, and Togo).
(9) Patent protection for pharmaceutical products was only introduced on December 11th 1991 in Peru, as in all other members of the Andean Community (Bolivia, Colombia, Ecuador, and Venezuela).
(10) Patent protection for pharmaceutical products has only been available in Thailand since September 30th 1992, including pending applications at this date.
(11) In Uganda, patents are granted for 15 years from the date of grant, and may be extended for 5 additional years if the patent is worked locally.
(12) Note that other patents protect aqueous solutions and flavoured-masqued compositions of ciprofloxacin.
(13) Coartem: name in poor countries/Riamet: name in rich countries. WO refers to patent applications filed under the system of the Patent Cooperation Treaty (PCT). The PCT allows patent applicants to file a kind of "worldwide" patent application, by designating countries among PCT Member States in which they intend to obtain a patent. However, the applicant must then confirm this wish in each designated country/region and the patent can only be granted by the patent office of the said country/region.
Where '?' appears, the information was not available.
| |
|
|
Expected (0) patent expiry date (patent number) in |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
INN (1) |
Originator's Trade mark |
Patent holder (2) (manufacturer) |
Basic patent priority date |
International patent application |
Representative European corresponding patent |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| |
|
|
|
|
|
Brazil (3) |
Cambodia (4) |
China (5) |
Guatemala (6) |
Kenya |
Malawi (7) |
OAPI (8) |
Peru (9) |
South Africa |
Thailand (10) |
Uganda (11) |
Ukraine |
Zambia (7) |
Zimbabwe |
Abacavir (racemic mixture) |
|
Wellcome (GSK) |
27.06.1988 (GB8815265) |
No |
EP0349242 |
27.06.08 (BR1100288) |
No |
No |
No |
26.06.09 (AP101) |
26.06.05 (AP101) |
No |
No |
25.06.09 (ZA8904837)No |
|
23.10.05 (AP101) |
No |
26.06.05 (AP101) |
26.06.09 (AP101) |
Abacavir (enantiomer) |
Ziagen |
Wellcome (GSK) |
22.12.1989 (US455201) |
No |
EP0434450 |
No |
No |
21.12.05 (CN1028106) |
No |
21.12.10 (AP196) |
21.12.06 (AP196) |
No |
No |
20.12.10 (ZA9010365)No |
|
30.06.07 (AP196) |
21.12.10 (UA29382) |
21.12.06 (AP196) |
21.12.10 (AP196) |
Didanosine - ddI |
|
USAGov (BMS) |
26.08.1985 (US769016) |
WO87/01284 |
EP0216510 |
No |
No |
No |
No |
No |
No |
No |
No |
No |
No |
No |
No |
No |
No |
improved oral formulation |
Videx |
BMS |
22.07.1991 (US733547) |
No |
EP0524579 |
No |
No |
21.07.07 (CN1042299) |
No |
No |
No |
No |
No |
20.07.12 (ZA9205484) |
07.07.12 (7600) |
No |
No |
No |
No |
Efavirenz |
Stocrin/Sustiva |
Merck (MSD, BMS) |
07.08.1992 (US926607) |
WO94/03440 |
EP0582455 |
07.08.12 (BR1100250) |
No |
06.08.13 (CN1051767) |
No |
No |
No |
No |
No |
06.08.13 (ZA9305724) |
30.07.13 (11367) |
No |
06.08.13 (UA42699) |
No |
No |
Indinavir (including sulfate) |
Crixivan |
Merck (MSD) |
08.11.1991 (US789508) |
WO93/09096 |
EP0541168 |
No |
No |
No |
No |
No |
No |
No |
No |
06.11.12 (ZA9208563) |
No |
No |
03.11.12 (UA45945) |
No |
No |
(related) Indinavir |
|
Merck |
07.05.1993 (US059038) |
WO94/26717 |
EP0696277 (withdrawn) |
No |
No |
under examination (CN1126469) |
No |
No |
WO94/26717? |
WO94/26717? |
No |
05.05.14 (ZA9403104) |
under examination (16620) |
No |
No |
No |
No |
Lamivudine - 3TC (including enantiomer) |
Epivir |
IAF Biochem (GSK) |
08.02.1989 (US308101) |
No |
EP0382526 |
No |
No |
08.02.05 (CN1033640) |
No |
08.02.10 (AP136) |
08.02.06 (AP136) |
08.02.10 (OA9193) |
No |
07.02.10 (ZA9000943) |
No |
05.08.06 (AP136) |
No |
08.02.06 (AP136) |
08.02.10 (AP136) |
enantiomer |
Epivir |
IAF Biochem |
02.05.1990 (GB9009861) |
WO91/17159 |
EP0625150 (rejected) |
No |
No |
30.04.06 (CN1036196) |
No |
02.05.11 (AP182) |
02.05.07 (AP182) |
02.05.11* (OA9559) |
No |
30.04.11 (ZA9103293) |
? |
30.06.07 (AP182) |
No |
02.05.07 (AP182) |
02.05.11 (AP182) |
cristalline form |
Epivir |
Glaxo |
03.06.1991 (GB9111902) |
WO92/21676 |
EP0517145 |
No |
No |
No |
No |
02.06.12 (AP300) |
02.06.08 (AP300) |
02.06.12* (OA9913) |
No |
02.06.12 (ZA9204007) |
? |
20.01.09 (AP300) |
02.06.12 (UA41265) |
02.06.08 (AP300) |
02.06.12 (AP300) |
Nelfinavir mesylate |
Viracept |
Agouron (Roche) |
07.10.1993 (US133543) |
WO95/09843 |
EP0722439 |
07.10.13 (BR1100166) |
No |
07.10.14 (CN1046269) |
No |
07.10.14 (AP600) |
07.10.14 (AP600) |
07.10.14* (OA10718) |
No |
07.10.14 (ZA9407815) |
No |
No |
No |
No |
No |
Nevirapine |
Viramune |
Boehringer |
17.11.1989 (US438923) |
No |
EP0429987 |
No |
No |
No |
No |
16.11.10 (AP179) |
16.11.06 (AP179) |
16.11.10 (OA9852) |
No |
18.11.10 (ZA9009246)No |
|
30.04.07 (AP179) |
17.11.09 (UA34420) |
16.11.06 (AP179) |
16.11.10 (AP179) |
Syrup formulation |
Viramune |
Boehringer |
25.08.1997 (US60/056803) |
? |
? |
? |
No |
? |
Potentially in the mailbox |
? |
? |
? |
under examination (718-1998) |
? |
under examination (41541/opp. filed) |
? |
11.08.18 (UA44370) |
? |
? |
Ritonavir |
Norvir |
Abbott |
29.12.1992 (US998114) |
WO94/14436 |
EP0674513 |
29.12.12 (BR1100661) |
No |
No |
No |
No |
No |
No |
No |
No |
No |
No |
? |
No |
No |
Combination w/lopinavir |
Kaletra |
Abbott |
13.12.1995 (US572226) |
WO97/21685 |
EP0882024 |
13.12.15 (BR1100397) |
No |
under examination (CN1208405) |
Potentially in the mailbox |
No |
No |
No |
No |
11.12.16 (ZA9610475) |
04.12.16 (13302) |
No |
? |
No |
No |
Saquinavir |
Fortovase |
Hoffmann-La Roche |
11.12.1989 (GB8927913) |
No |
EP0432695 |
No |
No |
10.12.05 (CN1034805) |
No |
No |
18.11.06 (MW9088) |
11.12.10 (OA9334) |
No |
03.12.10 (ZA9009743) |
No |
No |
? |
No |
13.11.10 (ZW90174) |
Stavudine - D4T |
Zerit |
Yale Univ. (BMS) |
17.12.1986 (US942666) |
No |
EP0273277 |
No |
No |
No |
No |
No |
No |
No |
No |
22.09.07 (ZA8707171) |
No |
No |
No |
No |
No |
Pro-drug |
|
BMS |
06.05.1988 (US190809) |
No |
EP0340778 (withdrawn) |
No |
No |
No |
No |
No |
No |
No |
No |
04.05.09 (ZA8903348)No |
|
No |
No |
No |
No |
Zidovudine - AZT |
Retrovir |
Glaxo Wellcome |
16.03.1985 (GB8506869) |
No |
EP0196185 |
No |
No |
No |
No |
14.03.06 (AP11) |
14.03.02 (AP11) |
No |
No |
13.03.06 (ZA8601933) |
No |
22.12.02 (AP11) |
? |
14.03.02 (AP11) |
14.03.06 (AP11) |
AZT - 3TC combination |
|
Glaxo Wellcome |
16.05.1991 (GB9110624) |
WO92/20344 |
EP0513917 |
No |
No |
15.05.07 (CN1045961) |
No |
No |
WO92/20344? |
11.05.12* (OA10058) |
No |
15.05.12 (ZA9203544) |
No |
No |
No |
No |
No |
Tablet formulation |
Combivir |
Glaxo Wellcome |
31.10.1996 (GB9622681) |
WO98/18477 |
EP0941100 (expected grant 28.05.03) |
under examination (BR9712614) |
No |
under examination (CN1241142) |
Potentially in the mailbox |
29.10.17 (AP1067) |
29.10.13 (AP1067) |
29.10.17* (OA11038) |
under examination
(965-1997) |
29.10.17 (ZA9709726) |
under examination
(37164/opp. filed) |
01.05.17 (AP1067) |
No |
No |
29.10.17 (AP1067) |
AZT + 3TC + abacavir |
Trizivir |
Glaxo Wellcome |
30.03.1995 (GB9506490) |
WO96/30025 |
EP0817637 |
under examination (BR9607851) |
No |
28.03.16 (CN1103593) |
Potentially in the mailbox |
28.03.16* (AP652) |
28.03.12* (AP652) |
WO96/30025? |
No |
27.03.16 (ZA9602477) |
under examination (28828) |
19.06.13* (AP652) |
WO96/30025? |
No |
28.03.16* (AP652) |
Tablet formulation |
Trizivir |
Glaxo Wellcome |
29.04.1998 (GB9809213) |
WO99/55372 |
EP1083932 (under examination) |
under examination (BR9910071) |
No |
WO99/55372? |
Potentially in the mailbox |
WO99/55372? |
WO99/55372? |
WO99/55372? |
No |
WO99/55372? |
? |
WO99/55372? |
WO99/55372? |
No |
WO99/55372? |
Footnotes:
(0) Except when stated differently, this expiry date is 20 years from the filling date, but note that the patent may expire before if the patent holder abandons it (i.e. stops paying the annual fees).
(1) Patents may be granted to protect the basic molecule of a medicine, but also e.g. to protect the manufacturing process, a specific therapeutic indication, or a specific formulation of the said molecule. Note that a product patent usually covers also a manufacturing process.
(2) Note that only the first patent holder is named where there are more than one.
(3) In Brazil, patent protection for pharmaceuticals was only introduced on May 14th 1997. However, between May 15th 1996 and May 15th 1997 it was possible to register a preexisting foreign patent or pending patent application in Brazil in order to obtain pipeline patent protection, i.e., patent protection for medicines which are patent protected abroad but which have not been marketed yet.
(4) There is no patent law in force in Cambodia. A draft Patent Law was passed by the National Assembly on November 28th 2002. This law is then supposed to go to the Senate for confirmation and is expected to be in force in 2003.
(5) Chinese Patent Law was amended, with effect on January 1st 1993, to extend patent protection from 15 to 20 years.
(6) Guatemala only introduced patent protection for pharmaceuticals on November 1st 2000.
(7) In Malawi and Zambia, patents are granted for an initial term of 16 years from the filing date, with a possible extension.
(8) OAPI patents are effective in the 16 member States of the Organisation Africaine de la Propriété Intellectuelle (Benin, Burkina Faso, Cameroon, Central African Rep., Congo, Ivory Coast, Gabon, Guinea, Guinea Bissau, Equatorial Guinea, Mali, Mauritania, Niger, Senegal, Chad, and Togo).
(9) Patent protection for pharmaceutical products was only introduced on December 11th 1991 in Peru, as in all other members of the Andean Community (Bolivia, Colombia, Ecuador, and Venezuela).
(10) Patent protection for pharmaceutical products has only been available in Thailand since September 30th 1992, including pending applications at this date.
(11) In Uganda, patents are granted for 15 years from the date of grant, and may be extended for 5 additional years if the patent is worked locally. WO refers to patent applications filed under the system of the Patent Cooperation Treaty (PCT). The PCT allows patent applicants to file a kind of "worldwide" patent application, by designating countries among PCT Member States in which they intend to obtain a patent. However, the applicant must then confirm this wish in each designated country/region and the patent can only be granted by the patent office of the said country/region.
WO? means that we don't know if the PCT application has been confirmed at national level.
* There is an error in the published patent document with regard to the filing date (see section 4). The estimated patent expiry date is therefore based on the assumed correct filing date.
Where '?' appears, the information was not available.
Loading...
